Last reviewed · How we verify
Cogentin (benzatropine)
Cogentin (generic name: benzatropine) is a Anticholinergic drug. It is currently FDA-approved (first approved 1954) for Arteriosclerotic Parkinsonism, Extrapyramidal disease, Parkinson's disease.
Benztropine is a small molecule medication used to treat movement disorders such as parkinsonism and dystonia, as well as extrapyramidal side effects of antipsychotics. It is taken by mouth or by injection into a vein or muscle and works as a centrally acting anticholinergic and antihistamine.
At a glance
| Generic name | benzatropine |
|---|---|
| Drug class | Anticholinergic |
| Target | Muscarinic acetylcholine receptor M1 |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1954 |
Approved indications
- Arteriosclerotic Parkinsonism
- Extrapyramidal disease
- Parkinson's disease
- Parkinsonism
- Postencephalitic parkinsonism
Common side effects
Drug interactions
- Ioflupane I-123
Key clinical trials
- Anticholinergic Deprescription in Schizophrenia (PHASE4)
- CLOZAPINE Response in Biotype-1 (PHASE4)
- Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders (NA)
- Patient Education and Duloxetine, Alone and in Combination, for Patients With Multisystem Functional Somatic Disorder (PHASE4)
- Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fasting Conditions (PHASE1)
- Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fed Conditions (PHASE1)
- A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection (PHASE2)
- Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cogentin CI brief — competitive landscape report
- Cogentin updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Cogentin
What is Cogentin?
What is Cogentin used for?
What is the generic name of Cogentin?
What drug class is Cogentin in?
When was Cogentin approved?
What development phase is Cogentin in?
What does Cogentin target?
Related
- Drug class: All Anticholinergic drugs
- Target: All drugs targeting Muscarinic acetylcholine receptor M1
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Arteriosclerotic Parkinsonism
- Indication: Drugs for Extrapyramidal disease
- Indication: Drugs for Parkinson's disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing